NCT05748392撤回不适用
A Post-market, Multicenter, Prospective, Single-arm Study Evaluating Safety and Performance of the Veraflo™ Cleanse Choice Complete™ Dressing
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- ADE/SADE
研究概览
简要总结
The purpose of this external clinical study is to demonstrate the safety and performance of the Veraflo™ Cleanse Choice Complete™ Dressing Kit which will be used in conjunction with the V.A.C.® Ulta™ Therapy Unit, utilizing V.A.C. Veraflo™ Therapy instillation functions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Subject is pregnant prior to application of the initial dressing*
- •*Women who have had surgical sterilization by a medically accepted method (i.e. tubal ligation, hysterectomy, or oophorectomy) or are post-menopausal, defined as not having menstruation for > 12 months will not be required to undergo pregnancy testing.
- •Subject has been diagnosed with a malignancy in the wound.
- •Subject has untreated osteomyelitis.
- •Subject has an untreated systemic infection.
- •Subject has active cellulitis in the peri-wound area.
- •Subject has a known allergy or hypersensitivity to study materials: dressing(s), and/or dressing components such as acrylic or silicone adhesives or polyurethane.
- •Subject has, in the opinion of the investigator, a clinically significant condition that would impair the Subject's ability to comply with the study procedures.
- •Subject has had radiation directly to the wound area.
- •Subject has been diagnosed with a major vascular deficit limiting arterial inflow to the wound region, as determined by the Investigator's interpretation of the Subject's medical history.
- •Subject has necrotic tissue with eschar present. NOTE: After debridement of necrotic tissue and complete removal of eschar, Veraflo™ Therapy may be used.
- •Subject is participating in another interventional clinical study or was enrolled in a clinical trial within the last 30 days of Visit
- •Subject has non-enteric or unexplored fistula.
- •Subject has a wound with any unexplored tunneling present.
- •Subject has inadequate hemostasis at the wound site, as determined by the investigator.
- •Subject has a wound with non-protected exposed vessels, anastomotic sites, organ, or nerves.
结局指标
主要结局
ADE/SADE
时间窗: Up to 14 days
Subject incidence of Adverse Device Events (ADEs) and Serious ADEs (SADEs) during the use of the device.
次要结局
- Total Wound Volume (%)(Up to 14 days)
- Total Wound Area (%)(Up to 14 days)
- Non-viable Tissue (%)(Up to 14 days)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place DressingWoundNCT06625385Solventum US LLC90
已完成
不适用
Investigation of the Ability of the TENA SmartCare Change Indicator to Reduce the Number of Manual Checks Between Changes of Absorbing Incontinence ProductsUrinary IncontinenceNCT04846270Essity Hygiene and Health AB35
终止
不适用
IntErnational Long-term Follow-up Study of Patients With Uncontrolled HyperTensioNBlood PressureHypertensionNCT01705080Abbott Medical Devices276
招募中
不适用
Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert in Patient With Acute Rhinitis Associated With Nasal ObstructionAcute RhinitisNasal ObstructionRhinosinusitisRhinopharyngitisAllergic RhinitisNCT06580210Laboratoires Gilbert114
终止
不适用
A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02158078CeQur Corporation8